Neostigmine - Avadel Pharmaceuticals

Drug Profile

Neostigmine - Avadel Pharmaceuticals

Alternative Names: Bloxiverz; Neostigmine methylsulfate

Latest Information Update: 09 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eclat Pharmaceuticals
  • Developer Avadel Pharmaceuticals
  • Class Antiglaucomas; Quaternary ammonium compounds
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neuromuscular blockade

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 29 Jul 2013 Launched for Neuromuscular blockade in USA (IV) - first global launch
  • 31 May 2013 Registered for Neuromuscular blockade in USA (IV) - first global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top